A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10328169" target="_blank" >RIV/00064203:_____/16:10328169 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/16:10328169

Result on the web

<a href="http://dx.doi.org/10.1111/dom.12682" target="_blank" >http://dx.doi.org/10.1111/dom.12682</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dom.12682" target="_blank" >10.1111/dom.12682</a>

Result language

angličtina

Original language name

A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins

Original language description

Gliptins act by increasing endogenous incretin levels. Glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic peptide receptor (GIPR) are their indirect drug targets. Variants of GLP1R and GIPR have previously been associated with the incretin effect. The aim of the present pilot study was to examine associations of the GLP1R and GIPR gene variants with the glycaemic response to gliptins. A total of 140 consecutive patients with type 2 diabetes were followed-up 6 months after initiation of gliptin treatment. GLP1R rs6923761 (Gly168Ser) and GIPR rs10423928 genotyping was performed using real-time PCR, with subsequent high-resolution melting analysis. The main study outcome was reduction in glycated haemoglobin (HbA1c) after treatment. GLP1R Gly168Ser variant was significantly associated with reduction in HbA1c in an additive model (beta = -0.33, p = 0.011). The mean reduction in HbA1c in Ser/Ser homozygotes was significantly lower compared with Gly-allele carriers [0.12 +/- 0.23% vs. 0.80 +/- 0.09% (1.3 +/- 2.5 mmol/mol vs. 8.7 +/- 1.0 mmol/mol); p = 0.008]. In conclusion, GLP1R missense variant was associated with a reduced response to gliptin treatment. The genotype-related effect size of similar to 0.7% (8 mmol/mol) is equal to an average effect of gliptin treatment and makes this variant a candidate for use in precision medicine.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FB - Endocrinology, diabetology, metabolism, nutrition

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Diabetes, Obesity and Metabolism

ISSN

1462-8902

e-ISSN

—

Volume of the periodical

18

Issue of the periodical within the volume

9

Country of publishing house

GB - UNITED KINGDOM

Number of pages

4

Pages from-to

941-944

UT code for WoS article

000381664000013

EID of the result in the Scopus database

2-s2.0-84973531881